Highlights:

1.Clear MoA.

Trop2 is highly expressed in a variety of tumors, such as gastric cancer, pancreatic cancer, etc., and can promote tumor cell proliferation, invasion, metastasis, and other processes. Its high expression is closely related to shortened survival and poor prognosis of tumor patients.

2. Significant preclinical efficacy and less toxic & side effects.

a) The monotherapy inhibits pancreatic cancer tumor growth significantly.

b) The patented VK linker enhances the tissue penetration of payload and expands the therapeutic window, this asset has at least 400 times therapeutic window.

c) Excellent “bystander effects”

3. Global competitiveness:

The patented VK linker enables better tumor invasion in pancreatic and gastric cancers. Right now, no ADC is satisfactory in treating these two cancers.

4. Good market potential:

It is estimated that the number of new pancreatic cancer patients worldwide will reach 486,300 in 2028, and the pancreatic cancer drug market will reach US$4.1 billion; the global new gastric cancer patients will reach 1.1 million, and the gastric cancer drug market will reach US$4.4 billion.

Research progress：

1) Completed preclinical development and ready for IND filing.

2) The patented VK linker enhances the tissue penetration of payload and expands the therapeutic window.

3) The safety test has been completed, and there are no obvious toxic and side effects.